These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12498913)

  • 1. The NMDA receptor NR2B subtype selective antagonist Ro 25-6981 aggravates paroxysmal dyskinesia in the dt(sz) mutant.
    Richter A
    Eur J Pharmacol; 2003 Jan; 458(1-2):107-10. PubMed ID: 12498913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyamines in a genetic animal model of paroxysmal dyskinesia.
    Richter A; Morrison LD
    Brain Res; 2003 Aug; 981(1-2):168-73. PubMed ID: 12885438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of striatal NMDA receptor subunits in a model of paroxysmal dystonia.
    Avchalumov Y; Sander SE; Richter F; Porath K; Hamann M; Bode C; Kirschstein T; Köhling R; Richter A
    Exp Neurol; 2014 Nov; 261():677-84. PubMed ID: 25139804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NR2B-selective N-methyl-D-aspartate receptor antagonist Ro 25-6981 [(+/-)-(R*,S*)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine propanol] potentiates the effect of nicotine on locomotor activity and dopamine release in the nucleus accumbens.
    Kosowski AR; Liljequist S
    J Pharmacol Exp Ther; 2004 Nov; 311(2):560-7. PubMed ID: 15256539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition.
    Higgins GA; Ballard TM; Huwyler J; Kemp JA; Gill R
    Neuropharmacology; 2003 Mar; 44(3):324-41. PubMed ID: 12604092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidystonic efficacy of nitric oxide synthase inhibitors in a rodent model of primary paroxysmal dystonia.
    Richter A; Löschmann PA; Löscher W
    Br J Pharmacol; 2000 Nov; 131(5):921-6. PubMed ID: 11053212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine.
    Peeters M; Gunthorpe MJ; Strijbos PJ; Goldsmith P; Upton N; James MF
    J Pharmacol Exp Ther; 2007 May; 321(2):564-72. PubMed ID: 17267580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological and genetic evidence indicates that combined inhibition of NR2A and NR2B subunit containing NMDA receptors is required to disrupt prepulse inhibition.
    Spooren W; Mombereau C; Maco M; Gill R; Kemp JA; Ozmen L; Nakanishi S; Higgins GA
    Psychopharmacology (Berl); 2004 Aug; 175(1):99-105. PubMed ID: 14985927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist.
    Gill R; Alanine A; Bourson A; Buttelmann B; Fischer G; Heitz MP; Kew JN; Levet-Trafit B; Lorez HP; Malherbe P; Miss MT; Mutel V; Pinard E; Roever S; Schmitt M; Trube G; Wybrecht R; Wyler R; Kemp JA
    J Pharmacol Exp Ther; 2002 Sep; 302(3):940-8. PubMed ID: 12183650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket.
    Malherbe P; Mutel V; Broger C; Perin-Dureau F; Kemp JA; Neyton J; Paoletti P; Kew JN
    J Pharmacol Exp Ther; 2003 Dec; 307(3):897-905. PubMed ID: 14534359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of intrastriatal injections of glutamate receptor antagonists on the severity of paroxysmal dystonia in the dtsz mutant.
    Sander SE; Richter A
    Eur J Pharmacol; 2007 Jun; 563(1-3):102-8. PubMed ID: 17349621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The kynurenine 3-hydroxylase inhibitor Ro 61-8048 improves dystonia in a genetic model of paroxysmal dyskinesia.
    Richter A; Hamann M
    Eur J Pharmacol; 2003 Sep; 478(1):47-52. PubMed ID: 14555184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMDA NR2B subtype-selective receptor antagonists fail to antagonize electrically-precipitated seizures and elicit popping in mice.
    Burket JA; Mastropaolo J; Rosse RB; Katz EU; Deutsch SI
    Eur Neuropsychopharmacol; 2010 Mar; 20(3):207-10. PubMed ID: 20022475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NR2B subunit-specific NMDA antagonist Ro25-6981 inhibits the expression of conditioned fear: a comparison with the NMDA antagonist MK-801 and fluoxetine.
    Haller J; Nagy R; Toth M; Pelczer KG; Mikics E
    Behav Pharmacol; 2011 Apr; 22(2):113-21. PubMed ID: 21285873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of NMDA receptor subtype NR2B prevents seizures but not apoptosis of dentate gyrus neurons in bacterial meningitis in infant rats.
    Kolarova A; Ringer R; Täuber MG; Leib SL
    BMC Neurosci; 2003 Sep; 4():21. PubMed ID: 13129439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Ravenscroft P; McGuire S; Crossman AR; Menniti FS; Brotchie JM
    Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices.
    Rammes G; Hasenjäger A; Sroka-Saidi K; Deussing JM; Parsons CG
    Neuropharmacology; 2011 May; 60(6):982-90. PubMed ID: 21310164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of N-methyl-D-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias.
    Konitsiotis S; Tsironis C; Kiortsis DN; Evangelou A
    Psychopharmacology (Berl); 2006 Apr; 185(3):369-77. PubMed ID: 16518645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. State-dependent NMDA receptor antagonism by Ro 8-4304, a novel NR2B selective, non-competitive, voltage-independent antagonist.
    Kew JN; Trube G; Kemp JA
    Br J Pharmacol; 1998 Feb; 123(3):463-72. PubMed ID: 9504387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced attention and impulsive action following NMDA receptor GluN2B-selective antagonist pretreatment.
    Higgins GA; Silenieks LB; MacMillan C; Sevo J; Zeeb FD; Thevarkunnel S
    Behav Brain Res; 2016 Sep; 311():1-14. PubMed ID: 27180168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.